Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
Publishing timestamp: 2024-04-17 12:40:30
Summary
Eli Lilly's weight loss drug Zepbound and diabetes drug Mounjaro will be in short supply through the second quarter of this year due to increased demand. The company is working to increase production to meet the surge in demand. Other pharmaceutical companies are also facing similar shortages in weight loss and diabetes drugs.
Sentiment: NEUTRAL
Keywords: breaking news, health care industry, eli lilly and co, biotechnology, business news, business, pharmaceuticals, novo nordisk a/s, biotech and pharmaceuticals,